Dataset related to the article "Looking back to look forward: what to expect in a REDO surgery for a bioprosthesis replacement"

This record contains raw data related to the article “Looking back to look forward: what to expect in a REDO surgery for a bioprosthesis replacement”

REDO surgeries are becoming more common because an increased rate of bioprosthesis implantation. We performed Retrospective study on patients who underwent replacement of aortic and/or mitral bioprosthesis between 2005 and 2018 to evaluate intra-hospital mortality and morbidity. Univariate analysis is performed on the propensity score variables to determine predictors of mortality. A total of 180 patients were enrolled in the study: Group A (replacement of aortic bioprosthesis) with 136 patients (75.56%) and group B (replacement of mitral bioprosthesis ± aortic bioprosthesis) with 44 patients (24.44%). NYHA class≥3 and female sex were significantly more common in group B. Cardiopulmonary-bypass time and aortic cross-clamping time in group A and group B were, respectively, 154.95±74.35 and 190.25±77.44 (p=0.0005) and 115.99±53.54 and 144.91±52.53 (p=0.0004). Overall mortality was 8.89%. At propensity score adjustment, Group B was confirmed to have an increased risk of death (OR 3.32 CI 95% 1.02 – 10.88 p < 0.0001), gastro-intestinal complications (OR 7.784 CI 95% 1.005 – 60.282 p< 0.0002) and pulmonary complications ( OR 2.381 CI 95% 1.038 – 5.46 p < 0.0001). At the univariate analysis, endocarditis, cardiopulmonary-bypass and aortic cross clamping time, NYHA class≥3, urgency setting were significantly associated to death. Intra-hospital outcomes are acceptable regarding mortality and complications. Patients who need REDO surgery on mitral bioprosthesis have an increased risk of post operative pulmonary and gastro-intestinal complications and mortality. Therefore the choice of mitral bioprosthesis at time of first surgery should be carefully evaluated.